ID   Karpas-299-CR06
AC   CVCL_V404
SY   KARPAS-299-CR06; K299CR06
DR   cancercelllines; CVCL_V404
DR   Cosmic; 1849569
DR   Wikidata; Q54899496
RX   PubMed=23239810;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:7910; NPM1; Name(s)=NPM1-ALK (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1324 ! Karpas-299
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 18
//
RX   PubMed=23239810; DOI=10.1158/1541-7786.MCR-12-0569;
RA   Ceccon, Monica
RA   Mologni, Luca
RA   Bisson, William H.
RA   Scapozza, Leonardo
RA   Gambacorti-Passerini, Carlo
RT   "Crizotinib-resistant NPM-ALK mutants confer differential sensitivity
RT   to unrelated Alk inhibitors.";
RL   Mol. Cancer Res. 11:122-132(2013).
//